Analyst Scoreboard: 8 Ratings For Hologic
Portfolio Pulse from Benzinga Insights
Over the past three months, 8 analysts have evaluated Hologic (NASDAQ:HOLX), with ratings ranging from bullish to bearish. The average 12-month price target is $85.25, up from $84.29 previously. Analysts have maintained, raised, or lowered their ratings and price targets based on recent developments. Hologic has shown a revenue growth rate of 2.74%, a net margin of 19.23%, an ROE of 3.97%, and an ROA of 2.21%. The company operates in diagnostics, breast health, surgical, and skeletal health segments, with the majority of its revenue coming from the United States.
August 16, 2024 | 4:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Analysts have mixed ratings for Hologic (NASDAQ:HOLX) with an average 12-month price target of $85.25, up from $84.29. The company has shown positive financial metrics including a 2.74% revenue growth rate, a 19.23% net margin, and strong ROE and ROA.
The mixed analyst ratings and slight increase in the average price target suggest a cautiously optimistic outlook for Hologic. The company's strong financial metrics, including a high net margin and positive revenue growth, support a likely short-term positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100